ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cemdisiran

Also written as “Cemdisiran”, “Pozelimab + Cemdisiran” and “ALN-CC5”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Geographic Atrophy · Myasthenia Gravis · Glomerulonephritis, IGA · Atypical Hemolytic Uremic Syndrome, led by 2 companies.

Drug pageCemdisiran: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 27, 202110 company-led studies, 4 open or runningNext primary completion: Jul 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals74 open or runningphase 3since Sep 27, 2021Oct 21, 2020Jul 31, 2028phase 3 · NCT06541704
Alnylam Pharmaceuticalsits history only30 open or runningphase 2since Jan 23, 2015Jan 23, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2015Named cemdisiranINNProposed as its International Nonproprietary Name in WHO's List 114
  2. Oct 21, 2020First study: phase 1 study in HealthyFirst studyNCT04601844 · 19 enrolled · Belgium
  3. Mar 19, 2021Phase 2 study in Hemoglobinuria, ParoxysmalNCT04811716 · 24 enrolled · Hong Kong, Hungary, Korea, Republic of and more
  4. Apr 23, 2021Phase 2 study in Hemoglobinuria, ParoxysmalNCT04888507 · 6 enrolled · United Kingdom
  5. Sep 27, 2021Phase 3 study in Myasthenia GravisNCT05070858 · 288 enrolled · United States, Belgium, Brazil and more
  6. Feb 6, 2023Phase 3 study in Hemoglobinuria, ParoxysmalNCT05744921 · 202 planned · Brazil, Canada, Colombia and more
  7. Aug 2, 2024Phase 3 study in Macular DegenerationNCT06541704 · 975 planned · United States, Australia, Austria and more
  8. Aug 13, 2025Phase 3 study in Hemoglobinuria, ParoxysmalNCT07154745 · 35 planned · Brazil, Canada, Italy and more

Ahead

  1. Jul 31, 2028Primary completion: phase 3 study in Macular DegenerationNCT06541704
  2. Oct 10, 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT05744921
  3. Jan 18, 2030Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT07154745

TargetBeta

C5 →read by rule
“A proprietary formulation composed of small-interfering RNAs (siRNAs) directed against terminal complement component 5 (C5) of the complement pathway ”NCIt, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
ABBV-6628AbbViephase 21

Studies

All 7 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07154745Hemoglobinuria, Paroxysmal · Brazil, Canada, Italy and more3RecruitingJan 18, 203035
NCT06541704Macular Degeneration · United States, Australia, Austria and more3RecruitingJul 31, 2028975
NCT05744921Hemoglobinuria, Paroxysmal · Brazil, Canada, Colombia and more3RecruitingOct 10, 2028202
NCT05070858Myasthenia Gravis · United States, Belgium, Brazil and more3Active, not recruitingJul 8, 2025288
NCT04888507Hemoglobinuria, Paroxysmal · United Kingdom2CompletedMay 5, 20226
NCT04811716Hemoglobinuria, Paroxysmal · Hong Kong, Hungary, Korea, Republic of and more2CompletedOct 25, 202224
NCT04601844Healthy · Belgium1CompletedJul 23, 202119

How it is read

Names in the registry

  • “Cemdisiran”, 9 entries
  • “Pozelimab + Cemdisiran”, 1 entry
  • “ALN-CC5”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.